Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixotrigine extension in lumbosacral radiculopathy pain
NCT02957617Phase 2Terminated
- Sponsor
- Biogen
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of vixotrigine in neuropathic pain, sponsored by Biogen. Primary endpoint: Number of Participants experiencing Adverse Events (AE) and Serious Adverse Events (SAEs) up to 395 Days. Started Feb 2017; status: terminated.
02
Drugs
vixotrigine
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT02957617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957617.